Pulmatrix, Inc.
PULMAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2022 |
Earnings History
Next report: Apr 1, 2027 · EPS est. $-1.40| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.29 | $-2.00 | — | — |
| May 15, 2026 | $-0.32 | — | — | — |
| Feb 26, 2026 | $-0.25 | — | — | — |
| Oct 16, 2025 | $-0.24 | — | — | — |
| Aug 6, 2025 | $-0.42 | — | — | — |
| May 15, 2025 | $-0.50 | — | — | — |
| Mar 21, 2025 | $-0.54 | — | $3.0K | — |
| Nov 8, 2024 | $-0.71 | — | $366.0K | — |
News
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support IND-Enabling Development Ahead of Planned First-in-Human Trials
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night New “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far…
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) shares crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $1.50 and traded as low as $1.35. Pulmatrix shares last traded at $1.42, with a volume of 37,223 shares traded. Wall Street Analysts Forecast Growth Separately, Weiss
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 55,391 shares, an increase of 174.2% from the August 31st total of 20,198 shares. Currently, 1.5% of the company's stock are short sold. Based on an average
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity Eos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept.
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its second quarter financial results for 2026 and provi…